Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study
Extended follow-up confirms that first-line pembrolizumab plus chemotherapy improves efficacy and maintains a manageable safety profile compared with placebo plus chemotherapy, regardless of PD-L1 status, supporting this combination as a first-line treatment option for locally advanced or metastatic HER2-negative gastric or GEJ adenocarcinoma.
Abstract
Background KEYNOTE-859 showed a favorable benefit–risk profile for pembrolizumab plus chemotherapy compared with placebo plus chemotherapy, regardless of programmed death-ligand 1 (PD-L1) status, in participants with untreated locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. Outcomes after a median study follow-up of 4.5 years are reported. Patients and methods Overall, 1579 participants were randomly assigned 1 : 1 to pembrolizumab 200 mg or placebo plus chemotherapy every 3 weeks for ≤35 cycles. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival, objective response rate, and duration of response, all per RECIST v1.1 by blinded independent central review, and safety. Results The median study follow-up was 54.8 months (Q1-Q3, 46.8-62.1) at data cut-off (27 September 2024). In the intention-to-treat population, the median OS was 12.9 months for pembrolizumab plus chemotherapy compared with 11.5 months for placebo plus chemotherapy [hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.70-0.86]. Median OS was longer in the PD-L1 combined positive score (CPS) ≥1 (13.0 compared with 11.4 months; HR 0.74, 95% CI 0.66-0.84) and CPS ≥10 (15.8 compared with 11.8 months; HR 0.64, 95% CI 0.53-0.77) populations. Grade 3 or 4 treatment-related adverse events (AEs) occurred in 458 participants (58.3%) receiving pembrolizumab plus chemotherapy and 388 (49.3%) receiving placebo plus chemotherapy; grade 5 treatment-related AEs occurred in 8 participants (1.0%) and 16 participants (2.0%), respectively. Conclusions Extended follow-up confirms that first-line pembrolizumab plus chemotherapy improves efficacy and maintains a manageable safety profile compared with placebo plus chemotherapy, regardless of PD-L1 status, supporting this combination as a first-line treatment option for locally advanced or metastatic HER2-negative gastric or GEJ adenocarcinoma.
BACKGROUND
The randomized phase III study KEYNOTE-564 (NCT03142334) established pembrolizumab after surgery as the standard of care for patients with clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence. Prior analyses showed significantly improved disease-free survival (DFS) and overall survival (OS...
N. Haas, T. Powles, P. Tomczak et al.· Annals of Oncology· 1 citation
BACKGROUND
Adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved survival outcomes compared with neoadjuvant chemotherapy and surgery alone in participants with early-stage non-small-cell lung cancer (NSCLC) in the phase 3, randomized KEYNOTE-671 study. We report results from KEYNOTE-671...
H. Wakelee, J. Spicer, S. Gao et al.· Annals of Oncology· 1 citation
First-line tislelizumab plus chemotherapy provided sustained and clinically meaningful efficacy benefits over placebo plus chemotherapy and was tolerable, with no new safety signals for patients with unresectable, locally advanced, or metastatic ESCC and PD-L1 TAP score ≥5%.
D. Tougeron, J. Xu, E. Raymond et al.· ESMO Open· 0 citations
Importance
In the KEYNOTE-826 study, pembrolizumab (vs placebo) plus platinum-based chemotherapy (with or without bevacizumab) significantly improved progression-free survival and overall survival in participants with previously untreated persistent, recurrent, or metastatic cervical cancer at interim analysis 1 (media...
Kosei Hasegawa, N. Colombo, Krishnansu S. Tewari et al.· JAMA Oncology· 0 citations
RATIONALE-306 previously demonstrated improved overall survival (OS) in participants treated with tislelizumab plus chemotherapy versus those receiving placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma, with a minimum follow-up of approximately 15 months. Explo...
H. Yoon, Ken Kato, E. Raymond et al.· Nature Communications· 0 citations
Adding anti-PD-1 or anti-VEGF therapy to chemotherapy improves survival in patients with advanced gastric cancer, yet outcomes remain poor. This Phase Ib/II trial aimed to evaluate the efficacy and safety of combining sintilimab, the bevacizumab biosimilar IBI305, and CapeOX chemotherapy as a first-line treatment for p...
Mo Cheng, Peng-Fei Zhang, Qian-Cheng Hu et al.· Nature Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.